Recent data (AGENT IDE trial) have suggested that target vessel failure rates are significantly lower in paclitaxel-coated balloons versus conventional balloon angioplasties when used to treat in-stent restenosis (ISR). The drug-coated balloon for managing in-stent restenosis is a major step fo...